The Challenge of Subgroup Analyses — Reporting without Distorting
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Subgroup analyses are an important part of the analysis of a comparative clinical trial. However, they are commonly overinterpreted14 and can lead to further research that is misguided or, worse, to suboptimal patient care.Consider a randomized, clinical trial designed to determine whether a new treatment is more effective than an established treatment and assessed with a test, based on all randomized patients, of the null hypothesis that the treatments have equal efficacy, as measured in terms of the primary end point. Then, subgroup analyses are conducted to assess whether different types of patients respond differently to the new . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, analyses of HRQoL, IBS symptoms and stool characteristics data were performed in the subgroup of those definitely constipated subjects (n = 19), as defined on the only basis of <3 stools per week; a lower significance level (P < 0.001) was applied for judging results in this subgroup, as recommended.36”
Citations
Cites
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,837
Subgroup analysis and other (mis)uses of baseline data in clinical trials
Assmann, S. F., Pocock, S. J., Enos, L. E., & Kasten, L. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02039-0 · Cited by 1,167
Yusuf, S. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470010097038 · Cited by 1,014
Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction
Antman, E. M., Morrow, D. A., McCabe, C. H., Murphy, S. A., Ruda, M., Sadowski, Z., Budaj, A., López-Sendón, J. L., Guneri, S., Jiang, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060898 · Cited by 609
Cornell, R. G., Wolf, F. M., Bailar, J. C., & Mosteller, F. (1989) · Journal of the American Statistical Association · doi:10.2307/2289981 · Cited by 295
Yusuf, S. (1991) · JAMA · doi:10.1001/jama.266.1.93 · Cited by 129
Subgroups, treatment effects, and baseline risks: Some lessons from major cardiovascular trials
Parker, A. B., & Naylor, C. D. (2000) · American Heart Journal · doi:10.1067/mhj.2000.106610 · Cited by 61
Bailar, J. C. (1986) · Cited by 28
Cited by
Items 301–400 of 496
Age and Computed Tomography and Invasive Coronary Angiography in Stable Chest Pain
The DISCHARGE Trial Group, Bosserdt, M., Serna-Higuita, L. M., Feuchtner, G. M., Merkely, B. P., Kofoed, K. F., Benedek, T., Donnelly, P. M., Rodríguez-Palomares, J. F., Ērglis, A., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.0001 · Cited by 9
Wang, T., Pate, V., Wyss, R., Buse, J. B., Kosorok, M. R., & Stürmer, T. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae322 · Cited by 10
Deriving optimal data-analytic regimes from benchmarking studies
Doove, L. L., Wilderjans, T. F., Calcagnì, A., & Mechelen, I. V. (2016) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2016.10.016 · Cited by 9
“Rather than considering at this point tests for specific data types (which are prone to multiple testing problems - see, e.g., Lagakos, 2006), one may wish to check this by a global test of the null hypothesis of absence of a qualitative or disordinal interaction.”
BackgroundThe association between facility volume and overall survival in patients with Merkel cell carcinoma
Yoshida, E. J., Luu, M., Freeman, M. L., Essner, R., Gharavi, N. M., Shiao, S. L., Clair, J. M., Hamid, O., Ho, A. S., & Zumsteg, Z. S. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.25931 · Cited by 9
“The effects from interactions were used to evaluate differences among baseline factors.(27) Given that 14 subgroups were investigated, a Bonferroni correction was applied to adjust for multiple hypothesis testing.”
MethodLipid Management in the Geriatric Patient
Nair, A. P., & Darrow, B. J. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.003 · Cited by 9
Erder, M. H., Signorovitch, J., Setyawan, J., Yang, H., Parikh, K., Betts, K. A., Xie, J., Hodgkins, P., & Wu, E. Q. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.689270 · Cited by 9
L’analyse des « Big Data » en recherche clinique
Thiébaut, R., Hejblum, B. P., & Richert, L. E. (2014) · Revue d Épidémiologie et de Santé Publique · doi:10.1016/j.respe.2013.12.021 · Cited by 10
“Il s’agit d’une augmentation inévitable du risque statistique de première espèce lors de la répétition des tests statistiques, tout comme dans le cas des analyses de sous-groupes dans un essai clinique [1].”
Tom, J. A., Sinsheimer, J. S., & Suchard, M. A. (2010) · The Annals of Applied Statistics · doi:10.1214/10-aoas349 · Cited by 9
“One strategy pertinent to massive data inference is stratification [Cressie, Olsen and Cook (1997), Kettenring (2009)], often undesirable because it comes shackled with the host of difficulties arising from subgroup analysis [Glymour et al. (1997), Lagakos (2006)].”
BackgroundMethodKovalchik, S. A., & Cumberland, W. G. (2012) · Biometrical Journal · doi:10.1002/bimj.201100167 · Cited by 9
Terman, S. W., Slinger, G., Koek, A. Y., Skvarce, J., Springer, M. V., Ziobro, J. M., Burke, J. F., Otte, W. M., Thijs, R. D., Lossius, M. I., et al. (2023) · Epilepsia Open · doi:10.1002/epi4.12880 · Cited by 8
“25 However, in addition to possible false positives due to multiple comparisons, 26 this conventional approach may also miss true differences—comparing groups based on only one factor at time does not represent the full range of differences between patients.”
BackgroundWittes, J. T. (2012) · Lecture notes in statistics · doi:10.1007/978-1-4614-5245-4_7 · Cited by 8
Sensitivity and Subgroup Analyses
Deshmukh, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-71921-0_9 · Cited by 8
Fares, W. H. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201411-2082le · Cited by 8
Nadel, F. M. (2010) · The Open Pediatric Medicine Journal · doi:10.2174/1874309901004010014 · Cited by 8
“Seventy-eight (83”
Management of early-stage lung cancer: past, present, and future adjuvant trials.
Strauss, G. M. (2006) · PubMed · Cited by 8
Hamza, A. S., Warczok, C., Meyberg-Solomayer, G., Takacs, Z. F., Juhasz-Böess, I., Solomayer, E., Radosa, M. P., Radosa, C. G., Stotz, L., Findeklee, S., et al. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05615-1 · Cited by 8
Glass, J. E., Ilgen, M. A., Winters, J. J., Murray, R. L., Perron, B. E., & Chermack, S. T. (2010) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2010.10400694 · Cited by 8
“…instances where the pre dictors are dichotomous and the power to detect potential effects is low, a risk group analysis can provide information to complement statistical findings when relationships are conditional on a third variable (e.g. suicide attempt history) (Lagakos 2006; Aneshensel 2002).”
BackgroundKastrati, L., Farina, S., Gris, A. V., Raeisi‐Dehkordi, H., Llanaj, E., Quezada‐Pinedo, H. G., Bally, L., Muka, T., & Ioannidis, J. P. A. (2025) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2024-113359 · Cited by 8
“5 15–17 This may be even more relevant when these claims come from systematic reviews and meta-analyses.”
Addressing Systematic Missing Data in the Context of Causally Interpretable Meta-analysis
Barker, D., Bie, R., & Steingrimsson, J. A. (2023) · Prevention Science · doi:10.1007/s11121-023-01586-2 · Cited by 7
“Articulating the approaches and challenges of these efforts is beyond the scope of this manuscript (Dahabreh et al., 2016; Hu, 2023; Kent et al., 2020; Lagakos, 2006; Wang & Ware, 2011).”
MethodHilvers, P. S., & Thammasitboon, S. (2013) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000000012 · Cited by 7
“This finding could possibly occur by chance due to multiple subgroup analyses, which often increase probability of false-positive findings (30).”
BackgroundA clustering method to identify who benefits most from the treatment group in clinical trials
Lee, B. S., Sen, P. K., Park, N. S., Boothroyd, R. A., Peters, R. H., & Chiriboga, D. A. (2014) · Health Psychology and Behavioral Medicine · doi:10.1080/21642850.2014.924857 · Cited by 8
O’Connell, M. J., & Rosenheck, R. A. (2018) · Oxford University Press eBooks · doi:10.1093/oso/9780190695132.003.0005 · Cited by 10
Bornkamp, B., Zaoli, S., Azzarito, M., Martin, R., Müller, C. P., Moloney, C., Capestro, G., Ohlssen, D. I., & Baillie, M. (2024) · Pharmaceutical Statistics · doi:10.1002/pst.2368 · Cited by 8
“It is well-known to be prone to conclusions based on statistical analyses that later could not be reproduced in follow-up trials [38, 2, 33, 28, 3, 20, 1, 12].”
BackgroundSignal Transduction Pathways as Therapeutic Targets in Cancer Therapy
Milella, M., Ciuffreda, L., & Bria, E. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0507-9_2 · Cited by 8
“predictive role of the marker should not be addressed with separate comparison in M+ and M– patients, because this approach, as stated before, would be associated with a high risk of false results [243].”
BackgroundResultStatistical Interactions in a Clinical Trial
Ting, N. (2017) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479017716491 · Cited by 7
Evaluating the Role of Family Context Within a Randomized Adolescent HIV-Risk Prevention Trial
Barker, D., Hadley, W. S., McGee, H. A., Donenberg, G. R., DiClemente, R. J., & Brown, L. K. (2019) · AIDS and Behavior · doi:10.1007/s10461-019-02400-3 · Cited by 7
Interaction effects and subgroup analyses in clinical trials: more than meets the eye?
Sevdalis, N., & Jacklin, R. (2008) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2007.00872.x · Cited by 7
“on the basis of the number of subgroup comparisons that they perform) the criterion that they use to assess the significance of their results [3–5].”
BackgroundMethodInfluentialThe Challenge of Subgroup Analyses
Eisner, M. D. (2006) · New England Journal of Medicine · doi:10.1056/nejmc061335 · Cited by 7
Exploration of the regional effects of colchicine in the LoDoCo2 trial
Budgeon, C. A., Nidorf, S. M., Mosterd, A., Fiolet, A. T. L., Eikelboom, J. W., O’Halloran, S., Joyce, D., Schut, A., Tijssen, J. G. P., Cornel, J. H., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.09.006 · Cited by 6
Bellavia, A., Ran, X., Zimerman, A., Antman, E. M., Giugliano, R. P., Morrow, D. A., & Murphy, S. A. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107778 · Cited by 9
Subgroup identification by recursive segmentation
Hapfelmeier, A., Ulm, K., & Haller, B. (2018) · Journal of Applied Statistics · doi:10.1080/02664763.2018.1444152 · Cited by 7
“The exploration of subgroups is the subject of controversial debate in many high ranked medical journals [26,35,44] since post-hoc procedures may lead to spurious, false-positive findings.”
BackgroundKaul, S. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.4332 · Cited by 6
Santacatterina, M., & Bottai, M. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12389 · Cited by 6
Bayesian Modeling Using Latent Structures
Wang, X. (2012) · DukeSpace (Duke University) · Cited by 8
Bayesian credible subgroup identification for treatment effectiveness in time-to-event data
Ngo, D. H., Baumgartner, R., Mt‐Isa, S., Feng, D., Chen, J., & Schnell, P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229336 · Cited by 6
Evaluating heterogeneity of treatment effects
Vijan, S. S. (2020) · Biostatistics & Epidemiology · doi:10.1080/24709360.2020.1724003 · Cited by 6
Subgroup discovery in non‐inferiority trials
Fazzari, M. J., & Kim, M. (2021) · Statistics in Medicine · doi:10.1002/sim.9118 · Cited by 6
Cipriani, M., Pichiorri, F., Colamarino, E., Toppi, J., Tamburella, F., Lorusso, M., Bigioni, A., Morone, G., Tomaiuolo, F., Santoro, F., et al. (2023) · Trials · doi:10.1186/s13063-023-07773-4 · Cited by 7
“Moreover, for each subgroup variable, statistical tests for interaction [12, 28] will be carried out using ANOVA including the intervention group (BCI-MI vs Control-MI) and its interaction with the sub-group covariate.”
MethodUsing clinical trial data to tailor adjuvant treatments for individual patients
Regan, M. M., & Gelber, R. D. (2007) · The Breast · doi:10.1016/j.breast.2007.07.016 · Cited by 6
“Cautious interpretation of retrospective subgroup analyses is required (11,12,13).”
BackgroundSubgroup Analyses in Nephrology Clinical Trials
Fishbane, S. N., Shah, H. H., Kataria, A., Shirazian, S., & Agarwal, R. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04870512 · Cited by 7
“As noted in the work by Lagakos (8), when 10 independent tests are conducted, each with a P value of 0.”
BackgroundInfluentialThe power of noise and the art of prediction
Xiao, Z., & Higgins, S. (2017) · International Journal of Educational Research · doi:10.1016/j.ijer.2017.10.006 · Cited by 7
“Subgroup analysis is notoriously difficult (Assmann et al., 2000; Lagakos, 2006; Petticrew et al., 2012; Song and Bachmann, 2016; Wang et al., 2007), but it is a step towards personalised intervention effect, which can be computed using predictive modelling and has the potential to solve the…”
BackgroundOutcome measures in pulmonary arterial hypertension associated with systemic sclerosis
Kowal‐Bielecka, O., Delcroix, M., Noordegraaf, A. V., Hoeper, M. M., & Naeije, R. (2008) · Rheumatology · doi:10.1093/rheumatology/ken308 · Cited by 6
“results [ 13 ]. Even more difficult is the assessment of long-term effects of drugs shown efficacious in short-term RCT, where one remains limited to registries with associated suboptimal levels of evidence.”
BackgroundAmiodarone and the risk of cancer: A nationwide population‐based study
Fares, W. H. (2013) · Cancer · doi:10.1002/cncr.28266 · Cited by 6
New Hope for Patients with Metastatic Hormone-Refractory Prostate Cancer
de Wit, R. (2006) · European Urology Supplements · doi:10.1016/j.eursup.2006.06.017 · Cited by 6
“The results of subgroup analyses should always be interpreted with caution because over-interpretation can lead to misguided research and, in the worse case, to suboptimal patient care [29].”
BackgroundPhysician Judgment in Cardiology
Ben‐Yehuda, O. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.026 · Cited by 6
Simon, E. G., Caille, A., Perrotin, F., & Giraudeau, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066677 · Cited by 6
“At least, if trialists mix these populations, randomisation should be stratified, statistical analysis should take into account this stratification [24] and a subgroup analysis should be correctly performed and reported [25].”
Aronson, D. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0801 · Cited by 6
“A qualitative (crossover or ‘‘effect reversal’’) interaction is one in which treatment is beneficial in some subgroups but harmful in others (8, 15, 29, 38).”
BackgroundMethodInfluentialClinical Trials of Heart Failure: Is There a Question of Sex?
Sohani, Z. N., Alyass, A., & Pilote, L. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.07.003 · Cited by 5
A platform for comparing subgroup identification methodologies
Ruberg, S. J., Zhang, Y., Showalter, H., & Shen, L. (2023) · Biometrical Journal · doi:10.1002/bimj.202200164 · Cited by 6
“…and examples than can be reasonably referenced here, though some good reading for a traditional perspective can be found across the clinical and statistical spectrum going back decades (Cui et al., 2002; Grouin et al., 2005; Lagakos et al., 2006; Peto, 2011; Sleight, 2000; Yusuf et al., 1991).”
BackgroundReichmann, W. M., LaValley, M. P., GAGNON, D. R., & Losina, E. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-21 · Cited by 5
“While for most RCTs the primary hypothesis is the overall comparison of two (or more) treatments, there has been a continuing discussion over the last two decades about the use of subgroup analyses and formal tests of interaction in RCTs [1-7].”
BackgroundInfluentialAnalyse en sous-groupes et Forest Plot : limites et intérêts
Filleron, T., Gilhodes, J., Delord, J., & Cabarrou, B. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.09.023 · Cited by 5
Taylor, P. J. (2018) · Synthese · doi:10.1007/s11229-018-01960-6 · Cited by 6
“More generally, as statisticians caution, the more subgroupings that are explored the more chance that a significant associationwill arise by chance; Lagakos (2006) recommends therefore tighter criteria for claiming that an association is statistically significant.”
BackgroundDai, J. Y., & LeBlanc, M. L. (2019) · Journal of the Royal Statistical Society Series C (Applied Statistics) · doi:10.1111/rssc.12366 · Cited by 10
“As noted extensively in the clinical literature, agnostic subgroup analyses for gene–treatment interactions without a prior hypothesis are highly exploratory with limited power (Assmann et al. , 2000; Lagakos, 2006).”
BackgroundBayesian Variable Selection in Cost-Effectiveness Analysis
Negrín, M. Á., Polo, F. J. V., Escobar, M. D. C. M., Moreno, E., & Girón, F. J. (2010) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph7041577 · Cited by 6
“It is important to recall that in conventional frequentist clinical trial protocols, it is mandatory to specify any intended subgroup analysis in advance, and drug regulatory agencies are very wary of allowing claims for subgroup effects, because of the risk of data dredging [59-61].”
BackgroundShould Subgroup Analysis of Randomized Clinical Trials Have a Direct Impact on Clinical Practice?
Bria, E., Maïo, M. D., Cuppone, F., Nisticò, C., Cognetti, F., & Giannarelli, D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0365 · Cited by 5
Laor, A., Bitterman, H., & Vardi, M. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-06-0404 · Cited by 4
“Testing for multiple comparisons results in considerably more stringent threshold P-value for statistical significance (19).”
BackgroundHuang, N., Liu, Q., Hua, S., Hua, Y., Wang, M., Li, J., Zheng, H., Chen, G., & Liao, Q. (2024) · Current Problems in Surgery · doi:10.1016/j.cpsurg.2024.101580 · Cited by 4
Stoddard, G., Cook, N. B., Wagner, S., Solano, L., Shepley, E., & Cramer, G. (2025) · Journal of Dairy Science · doi:10.3168/jds.2024-26068 · Cited by 4
Lazar, A., Gansky, S. A., Halstead, D. D., Slajs, A., & Weintraub, J. A. (2013) · PubMed · Cited by 6
Clinical Research and the Development of Medical Therapeutics
Antman, E. M. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0459 · Cited by 4
Norgard, N. B., & DiNicolantonio, J. J. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315584113 · Cited by 4
“Such results must be interpreted with caution, especially because of the increased risk of false positive results arising from multiple post hoc analyses [Lagakos, 2006; Wang et al. 2007].”
BackgroundUncovering individualised treatment effects for educational trials
Xiao, Z., Hauser, O., Kirkwood, C., Li, D. Z., Ford, T. J., & Higgins, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-73714-z · Cited by 5
Thybo, K. H., Hägi‐Pedersen, D., Wetterslev, J., Dahl, J. B., Jakobsen, J. C., Pedersen, N. A., Jakobsen, K., Bülow, H. H., Ibsen, L., Overgaard, S., et al. (2020) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.13496 · Cited by 4
“Weight, kg 95 (18) 88 (9) 86 (18) 79 (17)”
Efficacy of early use of remdesivir: a systematic review of subgroup analysis
Gil‐Sierra, M. D., Briceño-Casado, M. D. P., Rey, E. J. A. D., & Sánchéz‐Hidalgo, M. (2022) · Revista Española de Quimioterapia · doi:10.37201/req/154.2021 · Cited by 4
Competing events and costs of clinical trials: Analysis of a randomized trial in prostate cancer
Zakeri, K., Rose, B. S., D'Amico, A. V., Jeong, J., & Mell, L. K. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.03.018 · Cited by 4
“While some caution should be used in interpreting effects within subgroups that are defined post hoc [28], it is evident that the observed differences in the effect on MFS across”
Ernst, P., Franssen, E., Chan, C. K., Okell, M., O’Byrne, P. M., & Bai, T. R. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2007.08.008 · Cited by 4
“To ensure the validity of our findings, all of the potential predictors of response were defined a priori and were tested as formal statistical interactions.(9) By pooling the results of a number of studies evaluating the role of combination therapy as an initial treatment approach, this analysis has identified both a…”
MethodIdentification of drug-induced toxicity biomarkers for treatment determination
Lu, T., & Chen, J. J. (2015) · Pharmaceutical Statistics · doi:10.1002/pst.1684 · Cited by 4
Thalidomide in Small-Cell Lung Cancer: Is It a Tombstone?
Rossi, A., Gridelli, C., & Bria, E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.6951 · Cited by 4
Robust method for optimal treatment decision making based on survival data
Fang, Y., Zhang, B., & Zhang, M. (2021) · Statistics in Medicine · doi:10.1002/sim.9198 · Cited by 3
“Yi − (Xi; ̂) − HXi(Ai − ̂i) }2 , (3)”
BackgroundInfluentialDetecting Safety Signals Among Adverse Events in Clinical Trials
Zink, R. C. (2018) · ICSA book series in statistics · doi:10.1007/978-981-10-7826-2_7 · Cited by 3
Subgroup analysis of linear models with measurement error
Le, Y., Bai, Y., & Qin, G. (2023) · Canadian Journal of Statistics · doi:10.1002/cjs.11763 · Cited by 3
“However, this method is over-interpreted and may lead to misguided inference (Lagakos, 2006).”
MethodMazza, G. L., Culakova, E., Enserro, D. M., Dignam, J. J., & Unger, J. M. (2025) · JNCI Monographs · doi:10.1093/jncimonographs/lgae045 · Cited by 5
A novel high dimensional approach to assess heterogeneous treatment effect in claims data
Wang, T., Pate, V., Wyss, R., Buse, J. B., Kosorok, M. R., & Stürmer, T. (2025) · American Journal of Epidemiology · doi:10.1093/aje/kwaf127 · Cited by 3
Delmar, P., Irl, C., & Tian, L. (2017) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2017.01.007 · Cited by 5
Pending issues of standard approaches in oncology
Tryakin, A. A., Fedyanin, M. Y., Покатаев, И. А., & Petrovsky, A. V. (2020) · Practical oncology · doi:10.31917/2102081 · Cited by 3
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015) · Springer eBooks · doi:10.1007/978-3-319-18539-2_18 · Cited by 5
Peng, S., Lin, C., Chen, I., Shen, Y., Chang, D., Chen, T. W., Huang, S., Hu, F., & Lu, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6563 · Cited by 4
Statistical Analysis of Comet Assay Data
Lovell, D. P. (2016) · Royal Society of Chemistry eBooks · doi:10.1039/9781782622895-00551 · Cited by 3
Zambelli, A., Pappagallo, G. L., & Marchetti, P. (2020) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2019-0168 · Cited by 3
Fedyanin, M. Y., Максимовна, П. Е., Elsnukaeva, H., Tryakin, A. A., Покатаев, И. А., Bulanov, A., & Tjulandin, S. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-20-125-132 · Cited by 3
Olsen, M. K., Stechuchak, K. M., Oddone, E. Ž., Damschroder, L. J., & Maciejewski, M. L. (2021) · Health Services and Outcomes Research Methodology · doi:10.1007/s10742-021-00243-x · Cited by 4
“Historically, HTE was assessed by identifying subgroups stratified by one variable (e.g., male vs. female) and with statistical tests for treatment by subgroup interactions, which are easy to implement and intuitive to understand (Lagakos 2006; Alosh et al.”
MethodHETEROGENEITY IN COST-EFFECTIVENESS ANALYSIS:
Espinoza, M. (2012) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 4
Cost-Effectiveness of Clopidogrel: Seeing through the Smoke
Goldman, L., & Gaspoz, J. (2008) · Medical Decision Making · doi:10.1177/0272989x08318467 · Cited by 3
Wiseman, D. M., Kory, P. D., Mazzucco, D., & Ramesh, M. S. (2020) · medRxiv · doi:10.1101/2020.08.19.20178376 · Cited by 3
Farhat, L. C., Sugaya, L. S., Bloch, M. H., Childress, A. C., Cortese, S., Fatori, D., Salum, G. A., Rohde, L. A., & Polanczyk, G. V. (2025) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2025.09.012 · Cited by 2
Lai, Y., Her, Q. L., Zhang, Y., Xu, H., Kucharska‐Newton, A., Ji, D., Wu, G., Garden, G. A., Stürmer, T., Wang, T., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71178 · Cited by 3
“18,19 Recent advances in causal machine learning-based subgrouping algorithms, 20,21 notably the iterative causal forest (iCF), overcome these limitations, enabling subgroup identification in observational data while controlling confounding without requiring prior knowledge.”
Heesen, P., Feuerriegel, S., Ciobanu-Caraus, O., Ranft, A., Bhadri, V. A., Brichard, B., Collaud, S., Cyprová, S., Eich, H., Ek, T., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116825 · Cited by 2
Veenemans, J. (2012) · MalariaWorld journal · doi:10.5281/zenodo.10997433 · Cited by 3
“…about between-subgroup differences (Parker et al. 2000), whilst the p-value reported (0.07) (Sazawal et al. 2007) does not provide conclusive evidence for such effect modification by age, particularly in the context of a trial with multiple subgroup analyses (Lagakos 2006, Sun et al. 2010).”
ResultInfluentialRenin–angiotensin System Genes and Coronary Artery Calcification
Nsengimana, J., & Barrett, J. H. (2007) · Future Cardiology · doi:10.2217/14796678.3.6.587 · Cited by 2
Meta-analysis of prognostic and predictive factors: Towards individual participant data?
Faron, M., Pignon, J., & Paolettí, X. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.023 · Cited by 2
Specific treatment of acute ischemic stroke
Berge, E., & Sandercock, P. A. (2019) · Wiley eBooks · doi:10.1002/9781118492390.ch13 · Cited by 2
Minchin, M., Christiansen, C., Maconick, L. C., & Johnson, S. (2024) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-024-02748-5 · Cited by 2
“If a Bonferroni correction is adopted [32 ], meaning p < .025 to indicate significance for”
Wu, K., Zhang, X., Zheng, M., Zhang, J., & Chen, W. L. (2024) · Statistics in Medicine · doi:10.1002/sim.10212 · Cited by 2
“Furthermore, this approach supports the importance of pre-specifying the treatment interaction [9, 27, 28].”
Understanding heterogeneity of pragmatic trial results and subgroup analyses: The FIAT example
Raymond, J., & Darsaut, T. E. (2025) · Neurochirurgie · doi:10.1016/j.neuchi.2025.101683 · Cited by 2
Associations between floor material and E. coli contamination in rural Bangladeshi households
Tazin, S., Islam, M. S., Pickering, A. J., Kwong, L. H., Mertens, A., Niven, C. G., Arnold, B. F., Hubbard, A., Alam, M., Sen, D., et al. (2025) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2025.114641 · Cited by 2
Boden, W. E., Flather, M. D., & Bhatt, D. L. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6245-9 · Cited by 3
“and require further investigation to confirm results and understand the underlying reasons for the discrepancy [4, 6].”
BackgroundResultGooden, L. K., Metsch, L. R., Pereyra, M. R., Malotte, C. K., Haynes, L. F., Douaihy, A. B., Chally, J., Mandler, R. N., & Feaster, D. J. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1300-6 · Cited by 3
Das ABC der medizinischen Statistik: Klinische Studien lesen und verstehen
Labenz, J., & Kunz, C. U. (2010) · Der Internist · doi:10.1007/s00108-010-2581-x · Cited by 2
Gil‐Sierra, M. D., Rey, E. J. A. D., de la Lastra‐Romero, C. A., & Sánchéz‐Hidalgo, M. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211037322 · Cited by 2
“One of the most common mistakes is the assessment of an apparently selective benefit associated with an intervention in a subgroup of patients without statistical difference (namely interaction test) with respect to the complementary population subgroup.(10) What scientific evidence supports the use of docetaxel for p…”
MethodLubich, B., & Jeske, D. R. (2024) · Statistical Methods in Medical Research · doi:10.1177/09622802241229284 · Cited by 2
“5 Assessing the existence of subgroups with mixture model inference before proceeding with identifying subgroups based upon biomarkers can decrease the false discovery rate among sub-group analyses.”
Method
Metadata
- Authors
- Lagakos, S. W.
- Affiliations
- Harvard University (US)
- Corresponding author
- Lagakos, Stephen W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-04-20
- Volume
- 354
- Issue
- 16
- Pages
- 1667-1669
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085477178
- Semantic Scholar
- d03b954bb3525ed19f989e831c39645293c3c984
- Cited by
- 504
- References
- 7
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 23 · 2023: 13 · 2022: 14 · 2021: 13 · 2020: 21 · 2019: 34 · 2018: 21 · 2017: 21 · 2016: 23 · 2015: 29 · 2014: 21 · 2013: 26 · 2012: 29
- FWCI
- 40.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Keywords
- subgroup analysis, subgroup heterogeneity, overinterpretation, reporting bias, treatment effect heterogeneity, randomized controlled trials, primary endpoint
- MeSH terms
- Data Interpretation, Statistical, False Positive Reactions, Probability, Statistics as Topic, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.